William Blair analyst Matt Phipps has maintained their neutral stance on KROS stock, giving a Hold rating on July 24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Hold rating due to a combination of factors surrounding Keros Therapeutics’ strategic decisions and future plans. The company has decided to concentrate its efforts on the development of KER-065, particularly in the context of Duchenne muscular dystrophy (DMD), with a Phase II study set to commence in the first quarter of 2026. This strategic focus comes at the expense of discontinuing other projects, such as the development of cibotercept for pulmonary arterial hypertension, following less favorable trial results.
Additionally, Keros is undergoing significant organizational changes, including leadership restructuring and a substantial workforce reduction. The company also plans to return a significant amount of capital to shareholders, which indicates a shift in strategic priorities. These developments suggest a period of transition and uncertainty, which may have influenced the decision to maintain a Hold rating on the stock.
According to TipRanks, Phipps is an analyst with an average return of -4.8% and a 39.93% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Upstream Bio, Inc., and Amgen.
In another report released on July 24, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $14.00 price target.